{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:18:25Z","timestamp":1761895105831},"reference-count":85,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.3109\/10428190903207548","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T15:34:21Z","timestamp":1276875261000},"page":"1916-1930","source":"Crossref","is-referenced-by-count":35,"title":["Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies"],"prefix":"10.1080","volume":"50","author":[{"given":"Bertrand","family":"Coiffier","sequence":"first","affiliation":[{"name":"Hematology Department, Hospices Civils de Lyon, Pierre-Benite, France and Institut Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hospices Civils de Lyon, Pierre-Benite, France and Institut Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2009,12,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2798"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.28.727"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(98)00045-9"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1362"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(98)00048-4"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1935"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.171060098"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.171076798"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0080249"},{"key":"CIT0010","volume":"23","author":"Rivera VM","year":"2005","journal-title":"J Clin Oncol 2005 ASCO Ann Proc"},{"key":"CIT0011","first-page":"2476","volume":"45","author":"Metcalf CA","year":"2008","journal-title":"Proc Am Assoc Cancer Res"},{"key":"CIT0012","volume":"22","author":"Clackson T","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CIT0013","volume":"110","author":"Campbell RA","year":"2007","journal-title":"Blood"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.12.008"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0345"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2076"},{"key":"CIT0019","first-page":"419","volume":"1","author":"Dancey JE","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00117-3"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2005.09.009"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00636-6"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90570-3"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1038\/369756a0"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.2.815"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1011"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399408000586"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2367"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209887"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.20.7004-7014.2002"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2825"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2057"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2004.06.054"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-006-0038-1"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1038\/nature04869"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500169200"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.10.004"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015586"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.051078"},{"key":"CIT0041","first-page":"1433","volume":"90","author":"Hipp S","year":"2005","journal-title":"Haematologica"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404471"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0419"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.348"},{"key":"CIT0045","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1182\/blood.V83.12.3689.3689","volume":"83","author":"Rimokh R","year":"1994","journal-title":"Blood"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-103481"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.18.6733"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106148"},{"key":"CIT0049","doi-asserted-by":"crossref","unstructured":"Chiarini F, Fala F, Ricci F, et al PI-103, a dual inhibitor of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin, has cytotoxic activity in T-cell acute lymphoblastic leukemia cells: a new therapeutic strategy in T-cell acute lymphoblastic leukemia [abstract 1921]. Presented at: 50th ASH Annual Meeting and Exposition; San Francisco, CA: December 6\u20139, 2008. Blood 2008;112: (Abstract 1921)","DOI":"10.1182\/blood.V112.11.1921.1921"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2008.11.007"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-030833"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.4.7659"},{"key":"CIT0053","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.7616","volume":"24","author":"Farag SS","year":"2006","journal-title":"J Clin Oncol"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23580"},{"issue":"20","key":"CIT0056","volume":"26","author":"Smith SM","year":"2008","journal-title":"J Clin Oncol, 2008 ASCO Annual Meeting Proceedings"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0764"},{"key":"CIT0058","volume":"25","author":"Johnston PB","year":"2007","journal-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I"},{"key":"CIT0059","volume":"110","author":"Reeder CB","year":"2007","journal-title":"Blood"},{"key":"CIT0060","doi-asserted-by":"crossref","unstructured":"Ghobrial IM, Chuma S, Sam A, et al Phase II trial of the mTOR inhibitor RAD001 in relapsed and\/or refractory Waldenstrom macroglobulinemia: the Dana Farber Cancer Institute experience [abstract 1011].Presented at: 50th ASH Annual Meeting and Exposition; San Francisco, CA December 6\u20139, 2008. Blood 2008;112: (Abstract 1011).","DOI":"10.1182\/blood.V112.11.1011.1011"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1372"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.55.017"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0582-9"},{"key":"CIT0069","unstructured":"Witzig E, Habermann T, Reeder C, et al A phase II trial of the oral mTOR inhibitor everolimas in relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) [abstract 1081].Presented at: 14th Congress of the European Hematology Association; Berlin, Germany June 4\u20137 2009. Haematologica 2009;94(Suppl 2): (Abstract 1081)."},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-137752"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802531295"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802475295"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07595.x"},{"key":"CIT0074","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2834.2834","volume":"110","author":"Rheingold SR","year":"2007","journal-title":"Blood"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.12.077"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200043200"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2640"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2447"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210019"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0254"},{"key":"CIT0081","doi-asserted-by":"crossref","unstructured":"Ghobrial IM, Munshi N, Schlossman R, et al Phase I trial of CCI-779 (temsirolimus) and weekly bortezomib in relapsed and\/or refractory multiple myeloma [abstract 3696].Presented at: 50th ASH Annual Meeting and Exposition; San Francisco, CA December 6\u20139, 2008. Blood 2008;112: (Abstract 3696).","DOI":"10.1182\/blood.V112.11.3696.3696"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2494"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3381"},{"key":"CIT0084","first-page":"5716","volume":"63","author":"Ly C","year":"2003","journal-title":"Cancer Res"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01892.x"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10428190903207548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T22:58:47Z","timestamp":1591397927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3109\/10428190903207548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":85,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2009,11,19]]},"published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.3109\/10428190903207548"],"URL":"https:\/\/doi.org\/10.3109\/10428190903207548","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}